Cognitive correlates of visual hallucinations in dementia associated with Parkinson's disease

Movement Disorders

Volumn 26, Issue 5, 2011, Pages 824-829

  Bronnick, Kolbjorn ^a   Emre, Murat ^b   Tekin, Sibel ^c   Haugen, Siri B ^d   Aarsland, Dag ^a  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b ISTANBUL UNIVERSITY   (Turkey)

^c NOVARTIS PHARMA AG   (Switzerland)

^d AKERSHUS UNIVERSITY HOSPITAL   (Norway)

Author keywords

Attention; Cognition; Dementia; Parkinson's disease; Visual hallucinations

Indexed keywords

LEVODOPA; RIVASTIGMINE;

AGED; ARTICLE; ATTENTION; CLINICAL ASSESSMENT; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; DEPTH PERCEPTION; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; PARKINSON DISEASE; PRIORITY JOURNAL; REACTION TIME; RISK FACTOR; STIMULUS RESPONSE; TASK PERFORMANCE; VISUAL HALLUCINATION;

AGED; AGED, 80 AND OVER; COGNITION DISORDERS; DEMENTIA; FEMALE; HALLUCINATIONS; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; PSYCHIATRIC STATUS RATING SCALES; STATISTICS, NONPARAMETRIC;

EID: 79955078574     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23525     Document Type: Article

References (36)

1. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008; 23: 837-844.
2. Aarsland D, Bronnick K, Larsen JP, Tysnes OB, Alves G. Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study. Neurology 2009; 72: 1121-1126.
3. Mosimann UP, Rowan EN, Partington CE, et al. Characteristics of visual hallucinations in Parkinson disease dementia and dementia with lewy bodies. Am J Geriatr Psychiatry 2006; 14: 153-160.
4. Fenelon G, Alves G. Epidemiology of psychosis in Parkinson's disease. J Neurol Sci 2009; 289(1-2): 12-17
5. Ramirez-Ruiz B, Junque C, Marti MJ, Valldeoriola F, Tolosa E. Cognitive changes in Parkinson's disease patients with visual hallucinations. Dement Geriatr Cogn Disord 2007; 23: 281-288.
6. Factor SA, Molho ES, Podskalny GD, Brown D. Parkinson's disease: drug-induced psychiatric states. Adv Neurol 1995; 65: 115-138.
7. Merims D, Shabtai H, Korczyn AD, Peretz C, Weizman N, Giladi N. Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson's disease. J Neural Transm 2004; 111: 1447-1453.
8. Aarsland D, Larsen JP, Cummins JL, Laake K. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol 1999; 56: 595-601.
9. Burke W. The neural basis of Charles Bonnet hallucinations: a hypothesis. J Neurol Neurosurg Psychiatry 2002; 73: 535-541.
10. ffytche DH, Howard RJ. The perceptual consequences of visual loss: positive pathologies of vision. Brain 1999; 122 (Part 7): 1247-1260.
11. Levine DN, Finklestein S. Delayed psychosis after right temporoparietal stroke or trauma: relation to epilepsy. Neurology 1982; 32: 267-273.
12. Grossberg S. How hallucinations may arise from brain mechanisms of learning, attention, and volition. J Int Neuropsychol Soc 2000; 6: 583-592.
13. Collerton D, Perry E, McKeith I. Why people see things that are not there: a novel perception and attention deficit model for recurrent complex visual hallucinations. Behav Brain Sci 2005; 28: 737-757; discussion 757-794.
14. Diederich NJ, Goetz CG, Stebbins GT. Repeated visual hallucinations in Parkinson's disease as disturbed external/internal perceptions: focused review and a new integrative model. Mov Disord 2005; 20: 130-140.
15. Hobson JA, Pace-Schott EF. The cognitive neuroscience of sleep: neuronal systems, consciousness and learning. Nat Rev Neurosci 2002; 3 (9): 679-693.
16. Onofrj M, Thomas A, D'Andreamatteo G, et al. Incidence of RBD and hallucination in patients affected by Parkinson's disease: 8-year follow-up. Neurol Sci 2002; 23 (Suppl 2): S91-S94.
17. Barnes J, Boubert L. Executive functions are impaired in patients with Parkinson's disease with visual hallucinations. J Neurol Neurosurg Psychiatry 2008; 79: 190-192.
18. Santangelo G, Trojano L, Vitale C, et al. A neuropsychological longitudinal study in Parkinson's patients with and without hallucinations. Mov Disord 2007; 22: 2418-2425.
19. Ozer F, Meral H, Hanoglu L, et al. Cognitive impairment patterns in Parkinson's disease with visual hallucinations. J Clin Neurosci 2007; 14: 742-746.
20. Ramirez-Ruiz B, Junque C, Marti MJ, Valldeoriola F, Tolosa E. Neuropsychological deficits in Parkinson's disease patients with visual hallucinations. Mov Disord 2006; 21: 1483-1487.
21. Grossi D, Trojano L, Pellecchia MT, Amboni M, Fragassi NA, Barone P. Frontal dysfunction contributes to the genesis of hallucinations in non-demented Parkinsonian patients. Int J Geriatr Psychiatry 2005; 20: 668-673.
22. Barnes J, Boubert L, Harris J, Lee A, David AS. Reality monitoring and visual hallucinations in Parkinson's disease. Neuropsychologia 2003; 41: 565-574.
23. Meppelink AM, Koerts J, Borg M, Leenders KL, van Laar T. Visual object recognition and attention in Parkinson's disease patients with visual hallucinations. Mov Disord 2008; 23: 1906-1912.
24. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004; 351: 2509-2518.
25. Moller JC, Korner Y, Dodel RC, et al. Pharmacotherapy of Parkinson's disease in Germany. J Neurol 2005; 252: 926-935.
26. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308-2314.
27. Aarsland D, Larsen JP, Lim NG, et al. Range of neuropsychiatric disturbances in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1999; 67: 492-496.
28. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
29. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 141: 1356-1364.
30. Delis DC, Kaplan E, Kramer JH. Delis-Kaplan executive function system. San Antonio, Tex.: Psychological Corporation; 2001.
31. Simpson PM, Surmon DJ, Wesnes KA, Wilcock GK. The cognitive drug research computerized assessment system for demented patients: a validation study. Int J Geriatr Psychiatry 1991; 6: 95-102.
32. Miller JO, Low K. Motor processes in simple, go/no-go, and choice reaction time tasks: a psychophysiological analysis. J Exp Psychol Hum Percept Perform 2001; 27: 266-289.
33. Acion L, Peterson JJ, Temple S, Arndt S. Probabilistic index: an intuitive non-parametric approach to measuring the size of treatment effects. Stat Med 2006; 25: 591-602.
34. Kastner S, McMains SA, Beck DM. Mechanisms of selective attention in the human visual system: Evidence from neuroimaging. In: Gazzanigga MS, editor. The cognitive neurosciences. London: MIT Press; 2009.
35. Stebbins GT, Goetz CG, Carrillo MC, et al. Altered cortical visual processing in PD with hallucinations: an fMRI study. Neurology 2004; 63: 1409-1416.
36. Meppelink AM, de Jong BM, Renken R, Leenders KL, Cornelissen FW, van Laar T. Impaired visual processing preceding image recognition in Parkinson's disease patients with visual hallucinations. Brain 2009; 132(Pt 11): 2980-2993.